The LiFFT Study
Contact
Description
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of the study drug are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing sarcoma.
Eligibility and criteria
IRB Number:
23-020814
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
As a participant in the research, you will:
- Receive lurbinectedin (study drug) infusions
- Complete frequent clinic visits at CHOP Philadelphia
- Have frequent blood tests, including research blood tests to measure lurbinectedin levels
- Have periodic imaging performed to evaluate your response to treatment
- Have research tumor biopsies with anesthetic agent or general anesthesia (required if you are 18 years or older and your tumor is accessible (optional if you are under 18)
- Have research genetic tests (if not previously done clinically)
- Get optional research PET scans with a radioactive tracer
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.